Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KAF156 and Lumefantrine SDF in Uncomplicated P. falciparum Malaria
NCT03167242Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2017
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of ganaplacide in Plasmodium falciparum malaria, sponsored by Novartis. Started Aug 2017; status: completed.
02
Drugs
ganaplacide
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT03167242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03167242.